Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9Y680

UPID:
FKBP7_HUMAN

ALTERNATIVE NAMES:
23 kDa FK506-binding protein; FK506-binding protein 7; Rotamase

ALTERNATIVE UPACC:
Q9Y680; Q4ZG70; Q6V3B2; Q86U65; Q96DA4; Q9Y6B0

BACKGROUND:
The protein Peptidyl-prolyl cis-trans isomerase FKBP7, known for its alternative names such as 23 kDa FK506-binding protein and Rotamase, is essential in the protein synthesis process. It enhances the speed of protein folding, which is vital for proper cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Peptidyl-prolyl cis-trans isomerase FKBP7 offers a promising pathway for developing new therapeutic approaches. Its critical role in protein folding underscores its potential as a target in drug discovery efforts aimed at improving cellular health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.